PDF herunterladen
Semin Thromb Hemost 2017; 43(05): 493-499
DOI: 10.1055/s-0037-1602662
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Scoring Systems for Estimating the Risk of Recurrent Venous Thromboembolism

Ilaria Nichele
1   Hematology Department, S. Bortolo Hospital, Vicenza, Italy
,
Alberto Tosetto
1   Hematology Department, S. Bortolo Hospital, Vicenza, Italy
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
06. Juni 2017 (online)

    Lizenzen und Reprints

Abstract

The risk of recurrence after suspension of anticoagulant treatment in patients with a first episode of unprovoked venous thromboembolism (VTE) is highly variable from patient to patient. Not all patients are candidates for life-long anticoagulant therapy, essentially because there remain concerns for such an option regarding hemorrhagic complications and clinical monitoring. Thus, the “treat all” approach may be inadequate for some patients at low risk of relapse. Proper assessment of the recurrence risk may be helpful to decide the optimal therapeutic strategy in such patients. In recent years, attempts have been made to develop and validate clinical prediction rules to estimate the absolute risk of VTE recurrence in individual patients. This article highlights the advantages and disadvantages of such options, presenting three different prediction rules that have been published so far.

Keywords

venous thromboembolism - recurrence - clinical prediction rules - prognosis studies
 

  • References

  • 1 Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999; 159 (05) 445-453
    CrossrefPubMedGoogle Scholar
  • 2 Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158 (06) 585-593
    CrossrefPubMedGoogle Scholar
  • 3 Spencer FA, Emery C, Joffe SW. , et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis 2009; 28 (04) 401-409
    CrossrefPubMedGoogle Scholar
  • 4 Heit JA, Silverstein MD, Mohr DN. , et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86 (01) 452-463
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 5 Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5 (04) 692-699
    CrossrefPubMedGoogle Scholar
  • 6 Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet 2010; 376 (9757): 2032-2039
    CrossrefPubMedGoogle Scholar
  • 7 Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis 2016; 41 (01) 3-14
    CrossrefPubMedGoogle Scholar
  • 8 Iorio A, Kearon C, Filippucci E. , et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 2010; 170 (19) 1710-1716
    PubMedGoogle Scholar
  • 9 Boutitie F, Pinede L, Schulman S. , et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ 2011; 342: d3036
    CrossrefPubMedGoogle Scholar
  • 10 Prandoni P, Noventa F, Ghirarduzzi A. , et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92 (02) 199-205
    CrossrefPubMedGoogle Scholar
  • 11 Prandoni P, Lensing AW, Cogo A. , et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125 (01) 1-7
    CrossrefPubMedGoogle Scholar
  • 12 Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle PA. ; Subcommittees on Control of Anticoagulation, and Predictive and Diagnostic Variables in Thrombotic Disease. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost 2016; 14 (07) 1480-1483
    CrossrefPubMedGoogle Scholar
  • 13 Barnes GD, Kanthi Y, Froehlich JB. Venous thromboembolism: predicting recurrence and the need for extended anticoagulation. Vasc Med 2015; 20 (02) 143-152
    CrossrefPubMedGoogle Scholar
  • 14 Ensor J, Riley RD, Moore D, Snell KIE, Bayliss S, Fitzmaurice D. Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. BMJ Open 2016; 6 (05) e011190
    CrossrefPubMedGoogle Scholar
  • 15 Kearon C, Akl EA, Ornelas J. , et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
    CrossrefPubMedGoogle Scholar
  • 16 Rodger MA, Kahn SR, Wells PS. , et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008; 179 (05) 417-426
    CrossrefPubMedGoogle Scholar
  • 17 Douketis J, Tosetto A, Marcucci M. , et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med 2010; 153 (08) 523-531
    CrossrefPubMedGoogle Scholar
  • 18 Baglin T, Douketis J, Tosetto A. , et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost 2010; 8 (11) 2436-2442
    CrossrefPubMedGoogle Scholar
  • 19 Eichinger S, Weltermann A, Minar E. , et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med 2004; 164 (01) 92-96
    CrossrefPubMedGoogle Scholar
  • 20 Douketis JD, Gu CS, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med 2007; 147 (11) 766-774
    CrossrefPubMedGoogle Scholar
  • 21 Kyrle PA, Eischer L. Predicting the risk of recurrent venous thromboembolism. The Austrian study on recurrent venous thromboembolism (AUREC). Hamostaseologie 2013; 33 (03) 201-209
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 22 Douketis J, Tosetto A, Marcucci M. , et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ 2011; 342: d813
    CrossrefPubMedGoogle Scholar
  • 23 Roach REJ, Lijfering WM, Rosendaal FR, Cannegieter SC, le Cessie S. Sex difference in risk of second but not of first venous thrombosis: paradox explained. Circulation 2014; 129 (01) 51-56
    CrossrefPubMedGoogle Scholar
  • 24 Eichinger S, Kyrle PA. Duration of anticoagulation after initial idiopathic venous thrombosis--the swinging pendulum: risk assessment to predict recurrence. J Thromb Haemost 2009; 7 (Suppl 1): 291-295
    CrossrefPubMedGoogle Scholar
  • 25 Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 2013; 122 (05) 817-824
    CrossrefPubMedGoogle Scholar
  • 26 Pengo V, Ruffatti A, Legnani C. , et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011; 118 (17) 4714-4718
    CrossrefPubMedGoogle Scholar
  • 27 Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006; 166 (07) 729-736
    CrossrefPubMedGoogle Scholar
  • 28 Segal JB, Brotman DJ, Necochea AJ. , et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA 2009; 301 (23) 2472-2485
    CrossrefPubMedGoogle Scholar
  • 29 Lijfering WM, Middeldorp S, Veeger NJ. , et al. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Circulation 2010; 121 (15) 1706-1712
    CrossrefPubMedGoogle Scholar
  • 30 De Stefano V, Simioni P, Rossi E. , et al. The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S. Haematologica 2006; 91 (05) 695-698
    PubMedGoogle Scholar
  • 31 Brouwer JL, Lijfering WM, Ten Kate MK, Kluin-Nelemans HC, Veeger NJ, van der Meer J. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb Haemost 2009; 101 (01) 93-99
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 32 Pabinger I, Kyrle PA, Heistinger M, Eichinger S, Wittmann E, Lechner K. The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: a prospective cohort study. Thromb Haemost 1994; 71 (04) 441-445
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 33 Kyrle PA, Minar E, Hirschl M. , et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343 (07) 457-462
    CrossrefPubMedGoogle Scholar
  • 34 Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006; 296 (04) 397-402
    CrossrefPubMedGoogle Scholar
  • 35 Tripodi A, Legnani C, Chantarangkul V, Cosmi B, Palareti G, Mannucci PM. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost 2008; 6 (08) 1327-1333
    CrossrefPubMedGoogle Scholar
  • 36 Palareti G, Legnani C, Cosmi B. , et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003; 108 (03) 313-318
    CrossrefPubMedGoogle Scholar
  • 37 Eichinger S, Minar E, Bialonczyk C. , et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA 2003; 290 (08) 1071-1074
    CrossrefPubMedGoogle Scholar
  • 38 Palareti G, Cosmi B, Legnani C. , et al; PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355 (17) 1780-1789
    CrossrefPubMedGoogle Scholar
  • 39 Verhovsek M, Douketis JD, Yi Q. , et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 2008; 149 (07) 481-490 , W94
    CrossrefPubMedGoogle Scholar
  • 40 Kearon C, Spencer FA, O'Keeffe D. , et al; D-dimer Optimal Duration Study Investigators. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med 2015; 162 (01) 27-34
    CrossrefPubMedGoogle Scholar
  • 41 Carrier M, Rodger MA, Wells PS, Righini M, LE Gal G. Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost 2011; 9 (06) 1119-1125
    CrossrefPubMedGoogle Scholar
  • 42 Donadini MP, Ageno W, Antonucci E. , et al. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis. Thromb Haemost 2014; 111 (01) 172-179
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 43 Royston P, Moons KG, Altman DG, Vergouwe Y. Prognosis and prognostic research: developing a prognostic model. BMJ 2009; 338: b604
    CrossrefPubMedGoogle Scholar
  • 44 Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15 (04) 361-387
    CrossrefPubMedGoogle Scholar
  • 45 Steyerberg EW. Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. New York: Springer; 2009
    Google Scholar
  • 46 Debray TP, Moons KG, Ahmed I, Koffijberg H, Riley RD. A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data meta-analysis. Stat Med 2013; 32 (18) 3158-3180
    CrossrefPubMedGoogle Scholar
  • 47 Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood 2014; 123 (12) 1794-1801
    CrossrefPubMedGoogle Scholar
  • 48 Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139 (11) 893-900
    CrossrefPubMedGoogle Scholar
  • 49 Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010; 152 (09) 578-589
    CrossrefPubMedGoogle Scholar
  • 50 Rodger MA, Scarvelis D, Kahn SR. , et al. Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: a multi-national cohort. Thromb Res 2016; 143: 152-158
    CrossrefPubMedGoogle Scholar
  • 51 Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 2010; 121 (14) 1630-1636
    CrossrefPubMedGoogle Scholar
  • 52 Eichinger S, Heinze G, Kyrle PA. D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model. J Am Heart Assoc 2014; 3 (01) e000467
    CrossrefPubMedGoogle Scholar
  • 53 Marcucci M, Iorio A, Douketis JD. , et al. Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data. J Thromb Haemost 2015; 13 (05) 775-781
    CrossrefPubMedGoogle Scholar
  • 54 Tritschler T, Méan M, Limacher A, Rodondi N, Aujesky D. Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model. Blood 2015; 126 (16) 1949-1951
    CrossrefPubMedGoogle Scholar
  • 55 Tosetto A, Iorio A, Marcucci M. , et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 2012; 10 (06) 1019-1025
    CrossrefPubMedGoogle Scholar
  • 56 van Hylckama Vlieg A, Baglin CA, Luddington R, MacDonald S, Rosendaal FR, Baglin TP. The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study. J Thromb Haemost 2015; 13 (09) 1642-1652
    CrossrefPubMedGoogle Scholar
  • 57 Agnelli G, Buller HR, Cohen A. , et al; PLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368 (08) 699-708
    CrossrefPubMedGoogle Scholar
  • 58 Wu C, Alotaibi GS, Alsaleh K, Linkins L-A, McMurtry MS. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention. Thromb Res 2015; 135 (02) 243-248
    CrossrefPubMedGoogle Scholar